US 11,778,994 B2
NSG mice lacking MHC class I and class II
Michael A. Brehm, Dudley, MA (US); Michael V. Wiles, Mount Desert, ME (US); Dale L. Greiner, Hubbardston, MA (US); and Leonard D. Shultz, Bar Harbor, ME (US)
Assigned to The Jackson Laboratory, Bar Harbor, ME (US); and University of Massachusetts, Boston, MA (US)
Appl. No. 16/612,450
Filed by The Jackson Laboratory, Bar Harbor, ME (US); and University of Massachusetts, Boston, MA (US)
PCT Filed May 14, 2018, PCT No. PCT/US2018/032548
§ 371(c)(1), (2) Date Nov. 11, 2019,
PCT Pub. No. WO2018/209344, PCT Pub. Date Nov. 15, 2018.
Claims priority of provisional application 62/649,099, filed on Mar. 28, 2018.
Claims priority of provisional application 62/505,264, filed on May 12, 2017.
Prior Publication US 2020/0060245 A1, Feb. 27, 2020
Int. Cl. A01K 67/027 (2006.01)
CPC A01K 67/0276 (2013.01) [A01K 67/0278 (2013.01); A01K 2207/12 (2013.01); A01K 2217/075 (2013.01); A01K 2217/15 (2013.01); A01K 2227/105 (2013.01); A01K 2267/03 (2013.01)] 12 Claims
 
1. An immunodeficient non-obese diabetic mouse whose genome comprises: (a) a homozygous scid mutation in the endogenous Prkdc gene; (b) a homozygous null mutation in the endogenous Il2rg gene; (c) a homozygous null mutation in the endogenous H2-K1 gene; (d) a homozygous null mutation in the endogenous H2-D1 gene; and (e) a homozygous null mutation in the endogenous H2-Ab1 gene; wherein the genotype of the mouse is NOD.Cg-Prkdcscid H2-K1tm1Bpe H2-Ab1em1Mvw H2-D1tm1Bpe Il2rgtm1Wjl/SzJ, and the mouse lacks functional major histocompatibility complex (MHC) I, lacks functional MHC II, and has a human immunoglobulin G (IgG) clearance rate of no more than 60% two days after administration of human IgG to the mouse.